ARTICLE | Clinical News
Audentes reports updated Phase I/II myopathy data for AT132
May 25, 2018 3:32 PM UTC
Audentes Therapeutics Inc. (NASDAQ:BOLD) reported updated interim data from the first cohort of the open-label, dose-escalation, U.S. Phase I/II ASPIRO trial testing AT132 in patients with X-linked myotubular myopathy (XLMTM). The presentation at the American Society of Gene and Cell Therapy meeting in Chicago included additional follow-up from three patients and data from additional patients since the company first reported results in January (see BioCentury, Jan. 5).
AT132 is an adeno-associated viral serotype 8 (AAV8) vector delivering the myotubularin 1 (MTM1) gene...
BCIQ Target Profiles